Common use of Purchase Warrant Clause in Contracts

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. (“Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ ] [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] shares of common stock of the Company, par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the Purchase Warrant. This Purchase Warrant is initially exercisable at $[ ] per Share [125% of the price of the Shares sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. EX Xxxxxx, division of Benchmark Investments, LLC (“Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc.Warrant issued by T20 Holdings Ltd., a Delaware corporation Singapore incorporated public company limited by shares (the “Company”), the Holder is entitled, at any time or from time to time from [ [________________] [DATE THAT IS ONE YEAR AFTER SIX MONTHS FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ [____________] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [__________] shares of common stock Ordinary Shares of the Company, no par value $0.0001 per share (the “Ordinary Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [__________] per Share [125% of the price of the Shares sold in the Offering]Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Ordinary Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [ ], 2022, the date on which the Registration Statement on Form F-1 (File No. 333-266102) of the Company was declared effective by the Securities and Exchange Commission.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Kingswood Capital Corp. Markets, division of Benchmark Investments, Inc. (“Holder”), as registered owner of this Purchase Warrant, to TrovageneDigital Brands Group, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ [________________] [DATE THAT IS ONE YEAR AFTER SIX MONTHS FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ [____________] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] 100,000 shares of common stock of the Company, par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ ] 6.25 per Share [125% of the price of the Shares sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [ ], the date on which the Registration Statement on Form S-1 (File No. 333- 255193) of the Company was declared effective by the Securities and Exchange Commission.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis [Spartan Capital Corp. Securities, LLC][X.X. Xxxxxxxx & Co., Inc.] (“Holder”), as registered owner of this Purchase Warrant, to Trovagene, Xxxxxxx Inc., a Delaware corporation (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] _______, 2023 (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ ] [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] _______, 2028 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ an aggregate of [__] shares of common stock of the Companyshares, par value $0.0001 0.00001 per share (the “Shares”)) of the Company’s common stock, subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ ] per Share [125% of the a price of the Shares sold in the Offering]$____ per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price of $____ per Share (equal to 110% of the initial public offering price) or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean ___________, 2023, the date on which the Registration Statement on Form S-1, as amended (File No. 333-267907) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. (the “Holder”), as registered owner of this Purchase Warrant, to TrovageneBioRestorative Therapies, Inc., a Delaware corporation (the “Company”), the Holder is entitled, at any time or from time to time from [ ] [DATE •][DATE THAT IS ONE YEAR AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ [•] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [•] shares of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to closeclose in New York, New York, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [•] per Share [125% of the price of the Shares sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. This Purchase Warrant and each Purchase Warrant subsequently issued pursuant to the terms hereof which represents all or any portion of the interests represented by this Purchase Warrant, whether directly or indirectly, in each case to the extent such Purchase Warrant remains outstanding, is part of a series of one or more purchase warrants (the “Purchase Warrants”) which collectively entitle the holders thereof to subscribe for, purchase and receive up to [•] Shares, subject to adjustment following the exercise of any of the Purchase Warrants (the holders of the Purchase Warrants or the Shares underlying the Purchase Warrants are collectively referred to herein as the “Purchase Warrant Holders”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid pursuant to that certain Underwriting Agreement by or and between Northann Corp., a Nevada corporation (the “Company”), on behalf of Aegis the one hand, and Craft Capital Corp. Management, LLC (the “Holder”), on the other hand, dated [●], 2023 (the “Underwriting Agreement”), the Holder, as registered owner of this Purchase Warrant, to Trovagene, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] the date that is six months from [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] ●], 2023 (the “Commencement Exercise Date”), and at or before 5:00 p.m., Eastern time, [ ] on [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] ●], 2028, (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] such number of shares of common stock of the Company, par value $0.0001 0.001 per share (“Common Stock”) as equates to six percent (6.0%) of the aggregate number of shares of Common Stock sold in the Offering (the “Shares”), including any Common Stock sold upon exercise of the over-allotment option, subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [●] per Share [share of Common Stock (which is equal to one hundred and twenty-five percent (125% %) of the price of the Shares shares of Common Stock sold in the Offering]); provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share share of Common Stock and the number of Shares shares of Common Stock to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price as set forth above or the adjusted exercise priceprice as a result of the events set forth in Section 6 below, depending on the context. Capitalized terms not defined herein shall have the meaning ascribed to them in the Underwriting Agreement.

Purchase Warrant. THIS CERTIFIES THAT, pursuant to that certain Underwriting Agreement by and between True Leaf Medicine International Ltd., a Canadian corporation (the "Company") and Boustead Securities, LLC ("Boustead"), as representative (the "Representative") of the several underwriters listed in consideration of funds duly paid by Schedule A thereto (the "Underwriters"), dated _____ [●], 2017 (the "Underwriting Agreement"), Boustead (in such capacity with its permitted successors or on behalf of Aegis Capital Corp. (“assigns, the "Holder”"), as registered owner of this Purchase Warrant, to Trovagene, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] ______, 20__ (the “Commencement "Exercise Date”"), and at or before 5:00 p.m., Eastern time, [ ] [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] ______, 20__ (the “"Expiration Date”"), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [●] shares of common stock of the Company, no par value $0.0001 per share (the “"Shares”"), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law or executive order to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period commencing on the date hereof and ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ ] ___ per Share [125% (one hundred fifty percent (150.0%)) of the price of the Shares sold in the Offering]); provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “"Exercise Price” " shall mean the initial exercise price or the adjusted exercise [1] NTD: 6% of shares issued in offering. price, depending on the context. Any term not defined herein shall have the meaning ascribed thereto in the Underwriting Agreement.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid pursuant to that certain Underwriting Agreement by or and between MED EIBY HOLDING CO., LIMITED, a Cayman Islands exempted company with limited liability (the “Company”), on behalf of Aegis Capital Corp. one hand, and Boustead Securities, LLC (the “Holder”), on the other hand, dated __, 2023 (the “Underwriting Agreement”), the Holder, as registered owner of this Purchase Warrant, to Trovagene, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] ___, 2023 (the “Commencement Exercise Date”), and at or before 5:00 p.m., Eastern time, [ ] [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] on ____, 2028 (the “Expiration Date”, which date shall be no more than five years from the commencement of sales of the initial public offering pursuant to the Underwriting Agreement), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] _____ordinary shares of common stock (the “Shares”) of the Company, with $0.000002 par value $0.0001 per ordinary share (the “Ordinary Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law or executive order to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ ] ___ per Share [125% of the price of the Shares sold in the Offering]Ordinary Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Ordinary Share and the number of Ordinary Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price as set forth above or the adjusted exercise priceprice as a result of the events set forth in Section 6 below, depending on the context. Capitalized terms not defined herein shall have the meaning ascribed to them in the Underwriting Agreement.

Purchase Warrant. THIS CERTIFIES THATORDINARY SHARES PURCHASE WARRANT (this “Purchase Warrant”) certifies that, pursuant to that certain Underwriting Agreement by and between BloomZ Inc., a Cayman Islands exempted company (the “Company”) and Network 1 Financial Securities, Inc. (“Network 1”), dated [ ], 202_ (the “Underwriting Agreement”), Network 1 (in consideration of funds duly paid by such capacity with its permitted successors or on behalf of Aegis Capital Corp. (assigns, the “Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] ], 202_ (the “Commencement Date”)Exercise Date”)3, and at or before 5:00 p.m., Eastern time, [ ] [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] ], 202_2 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [●] shares of common stock Ordinary Shares of the Company, par value $0.0001 0.00000002 per share (the “Shares”)Shares”)4, subject to adjustment as provided in Section 6 5 hereof. If the Expiration Date is a day on which banking institutions are authorized by law or executive order to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period commencing on the date hereof and ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [●] per Share [125(120% of the price of the Shares sold in the Offering]); provided, however, that upon the occurrence of any of the events specified in Section 6 5 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. Any term not defined herein shall have the meaning ascribed thereto in the Underwriting Agreement. The Purchase Warrant is redeemable.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. (“Holder”), as registered owner of this Purchase Warrant (this “Purchase Warrant”), to Trovagene, Felicitex Therapeutics Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] beginning [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] ●], 2022 (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ ] on [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] ●], 2027 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [●] shares (the “Warrant Shares”) of Company common stock of the Companystock, par value $0.0001 per share (the “SharesCommon Stock”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is not a day on which banking institutions are authorized by law to closeBusiness Day, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereinBusiness Day. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [●] per Share [125% share of the price of the Shares sold in the Offering]Common Stock; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share share of Common Stock and the number of Shares shares of Common Stock to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context, and the term “Business Day” shall mean a day other than a Saturday, Sunday or any other day which is a federal legal holiday in the United States or any day on which the Federal Reserve Bank of New York is authorized or required by law or other governmental action to close, provided that the Federal Reserve Bank of New York shall not be deemed to be authorized or obligated to be closed due to a “shelter in place,” “non-essential employee” or similar closure of physical location at the direction of any governmental authority if the bank’s electronic funds transfer systems (including for wire transfers) are open for use by customers on such day.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. Revere Securities, LLC or R.X. Xxxxxxxx & Co., Inc. (each a “Holder,” and collectively the “Holders”), as registered owner of this Purchase Warrant, to Trovagene, Inc.Fxxxxx Corporation, a Delaware corporation Cayman Islands exempted company (the “Company”), each Holder is entitled, at any time or from time to time from [ ] [●], [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUSCOMMENCMENT OF SALES OF THE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ ] [●], [DATE THAT IS FIVE YEARS AFTER FROM THE DATE OF PROSPECTUSCOMMENCMENT OF SALES OF THE OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [●] ordinary shares of common stock of the Company, par value $0.0001 0.00001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [●] per Share [125% of the price of the Shares sold in the Offering]Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [●], 2023, the date on which the Registration Statement on Form F-1 (File No. 333-267778) of the Company was declared effective by the Securities and Exchange Commission.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid pursuant to that certain Underwriting Agreement by or and between VCI Global Limited, a British Virgin Islands company (the “Company”), on behalf of Aegis Capital Corp. one hand, and Boustead Securities, LLC (the “Holder”), on the other hand, dated __, 2022 (the “Underwriting Agreement”), the Holder, as registered owner of this Purchase Warrant, to Trovagene, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] ___, 2022 (the “Commencement Exercise Date”), and at or before 5:00 p.m., Eastern time, [ ] [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] on ____, 2027 (the “Expiration Date”, which date shall be no more than five years from the commencement of sales of the initial public offering pursuant to the Underwriting Agreement), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] _____ordinary shares of common stock (the “Shares”) of the Company, no par value $0.0001 per ordinary share (the “Ordinary Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law or executive order to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ ] ___ per Ordinary Share [125(100% of the price of the Shares sold in the Offering]Offering price); provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Ordinary Share and the number of Ordinary Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price as set forth above or the adjusted exercise priceprice as a result of the events set forth in Section 6 below, depending on the context. Capitalized terms not defined herein shall have the meaning ascribed to them in the Underwriting Agreement.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis [Xxxx Capital Corp. Partners, LLC/Feltl and Company, Inc.] (“Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc.The Joint Corp., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ [________________] [DATE THAT IS ONE YEAR AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and until at or before 5:00 p.m., Eastern time, [ [_________] [DATE THAT IS FIVE FOUR YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [____] shares of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period commencing on the Effective Date and ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [____] per Share [125% of the price of the Shares Company’s common stock sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [ ], the date on which the Registration Statement on Form S-1 (File No. 333-198860) of the Company was declared effective by the Securities and Exchange Commission.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. [__________] (“Holder”), as registered owner of this Purchase Warrant, to TrovageneFreeCast, Inc., a Delaware Florida corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER HUNDRED EIGHTY (180) DAYS FROM THE EFFECTIVE DATE OF PROSPECTUSTHE REGISTRATION STATEMENT] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ ] [DATE THAT IS FIVE (5) YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] shares of common stock of the Company, par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 5 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ ] per Share [125120% of the price of the Shares sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 5 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. This Warrant is being issued pursuant to the certain Underwriting Agreement (the “Underwriting Agreement”), dated ______, 2020, by and among the Company, the Holder and other underwriters named therein, providing for the public offering (the “Offering”) of shares of common stock, par value $0.0001 per share, of the Company. The term “Effective Date” shall mean the effective date of the Registration Statement on Form S-1 (File No. 333-236482). The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. (“Holder”), as registered owner of this Purchase Warrant, to TrovageneWearable Devices Ltd., Inc., a Delaware corporation an Israeli company (the “Company”), Holder is entitled, at any time or from time to time from [ ] beginning [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] ●], 2022 (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ ] on [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] ●], 2027 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [●] ordinary shares of common stock of the Company, no par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is not a day on which banking institutions are authorized by law to closeBusiness Day, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereinBusiness Day. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [●] per Share [125% of the price of the Shares sold in the Offering]Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context, and the term “Business Day” shall mean a day other than a Saturday, Sunday or any other day which is a federal legal holiday in the United States or any day on which the Federal Reserve Bank of New York is authorized or required by law or other governmental action to close, provided that the Federal Reserve Bank of New York shall not be deemed to be authorized or obligated to be closed due to a “shelter in place,” “non-essential employee” or similar closure of physical location at the direction of any governmental authority if the bank’s electronic funds transfer systems (including for wire transfers) are open for use by customers on such day.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly the payment of $100.00 and for other good and value consideration paid by or on behalf of Aegis Capital Corp. or its assigns (“Holder”), as registered owner of this Purchase Warrant, to TrovageneIntellicheck Mobilisa, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ [________________] [DATE THAT IS ONE YEAR AFTER FROM THE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and until at or before 5:00 p.m., Eastern time, [ [____________] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE REGISTRATION STATEMENT] (the “”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [____] shares of common stock of the Company, par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [___] per Share [125% of the price of the Shares sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean August 6, 2013, the date on which the Registration Statement on Form S-3 (File No. 333-189982) of the Company was declared effective by the Securities and Exchange Commission.

Purchase Warrant. THIS CERTIFIES THAT, pursuant to that certain Underwriting Agreement by and between., Code Rebel Corporation, a Delaware corporation (the “Company”) and Xxxxxxx Securities Inc. (“Xxxxxxx”) dated [●], 2015 (the “Underwriting Agreement”), Xxxxxxx (in consideration of funds duly paid by such capacity with its permitted successors or on behalf of Aegis Capital Corp. (assigns, the “Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS●], 20[__] (the “Commencement Exercise Date”)) [THE DATE THAT IS 180 DAYS AFTER THE EFFECTIVE DATE OF THE REGISTRATION STATEMENT], and at or before 5:00 p.m., Eastern time, [●], 20[ ] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [●] shares of common stock of the Company, par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law or executive order to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period commencing on the date hereof and ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [●] per Share ([125% 100.0]% of the price of the Shares sold in the Offering]); provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. Any term not defined herein shall have the meaning ascribed thereto in the Underwriting Agreement.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. (“Holder”), as registered owner of this Purchase Warrant, to TrovageneEyegate Pharmaceuticals, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ [________________] [DATE THAT IS ONE YEAR AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and until at or before 5:00 p.m., Eastern time, [ [____________] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [____] shares of common stock of the Company, par value $0.0001 0.01 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [___] per Share [125% of the price of the Shares Company’s common stock sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [ ], the date on which the Registration Statement on Form S-1 (File No. 333-xxxxxxx) of the Company was declared effective by the Securities and Exchange Commission.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid pursuant to that certain Underwriting Agreement by or and between Huarui International New Material Limited, a British Virgin Islands company limited by shares (the “Company”), on behalf of Aegis Capital Corp. one hand, and Univest Securities, LLC (the “Holder”), on the other hand, dated [ ● ], 2021 (the “Underwriting Agreement”), the Holder, as registered owner of this Purchase Warrant, to Trovagene, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] ● ], 2021 (the “Commencement Exercise Date”), and at or before 5:00 p.m., Eastern time, on [ ] [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] ● ], 2025, (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] such number of ordinary shares of common stock of the Company, par value $0.0001 0.0083 per ordinary share (the “Ordinary Shares”) as equates to [ ● ] percent ([ ● ] %)2 of the Ordinary Shares sold in the Offering (the “Shares”), excluding any Ordinary Shares sold as result of the exercise by the underwriters of their over-allotment option, subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ ● ] per Ordinary Share [125% (115%) of the price of the Ordinary Shares sold in the Offering]); provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Ordinary Share and the number of Ordinary Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price as set forth above or the adjusted exercise priceprice as a result of the events set forth in Section 6 below, depending on the context. Capitalized terms not defined herein shall have the meaning ascribed to them in the Underwriting Agreement.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. [__________] (“Holder”), as registered owner of this Common Stock Purchase Warrant (this “Purchase Warrant”), to TrovageneAcurx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [●], [DATE THAT IS ONE YEAR AFTER 180 DAYS FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ [●], 202[6] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] shares (the “Shares”) of common stock of the Company, par value $0.0001 0.001 per share (the “SharesCommon Stock”), subject to adjustment as provided in Section 6 5 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [●] per Share [125% of the price of the Shares sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 5 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. This Purchase Warrant is being issued pursuant to the certain Underwriting Agreement (the “Underwriting Agreement”), dated [●], 2021, by and among the Company, the Representative and other underwriters named therein, providing for the public offering (the “Offering”) of shares of Common Stock. The term “Effective Date” shall mean the effective date of the Registration Statement on Form S-1 (File No. 333-[___]). The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. Initially capitalized terms not otherwise defined herein shall have the meanings given to those terms in the Underwriting Agreement.

Purchase Warrant. THIS CERTIFIES THAT, pursuant to that certain Underwriting Agreement by and between., Dragon Vxxxxxx Xxxxxxxxxxxxx Limited, a Cayman Islands corporation (the “Company”) and Boustead Securities, LLC (“Boustead”), as Representative of the several underwriters, dated [●], 2017 (the “Underwriting Agreement”), Boustead (in consideration of funds duly paid by such capacity with its permitted successors or on behalf of Aegis Capital Corp. (assigns, the “Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS●], 20[__] (the “Commencement Exercise Date”)) [THE DATE THAT IS 180 DAYS AFTER THE EFFECTIVE DATE OF THE REGISTRATION STATEMENT], and at or before 5:00 p.m., Eastern time, [●], 20[ ] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [●] shares of common stock Ordinary Shares of the Company, par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law or executive order to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period commencing on the date hereof and ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [●] per Share [125(100% of the price of the Shares sold in the Offering]); provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. Any term not defined herein shall have the meaning ascribed thereto in the Underwriting Agreement.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. (“Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc.Alcobra Ltd., a Delaware Israeli corporation (the “Company”), Holder is entitled, at any time or from time to time from [ time to time, in whole or in part, during a period commencing one year (the “First Anniversary”) from [_______________] [DATE THAT IS ONE YEAR AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ ] [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] (the “Expiration Date”), but not thereafter, ) to subscribe for, purchase and receive, in whole or in part, up to [ an aggregate of [____] shares of common stock of the Companyordinary shares, par value $0.0001 NIS 0.01 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If hereof the Expiration Date is a day on which banking institutions are authorized rights granted by law this Purchase Warrant, including the exercise price per Share and the number of Shares to closebe received upon such exercise, then shall be adjusted as therein specified, as follows: (i) one third of this Purchase Warrant may be exercised will have an exercise period of 12 months beginning on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration DateFirst Anniversary, the Company agrees not to take any action that would terminate the Purchase Warrant. This Purchase Warrant is initially exercisable at an initial exercise price per Ordinary Share of $[ [•] per Share [125150.0% of the initial public offering price per share of ordinary share]; (ii) one third of this Purchase Warrant will have an exercise period of 18 months beginning on the First Anniversary, at an initial exercise price per Ordinary Share of $[•] [200.0% of the Shares sold in the Offeringinitial public offering price per share of ordinary share]; and (iii) one third of this Purchase Warrant will have an exercise period of 24 months beginning on the First Anniversary, at an initial exercise price per share of Ordinary Share of $[•], [250.0% of the initial public offering price per share of ordinary share] (each an ”Expiration Date”), provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. If an applicable Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on applicable Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. The term “Exercise Price” shall mean mean, as the case maybe, the applicable initial exercise price prices or the adjusted applicable exercise priceprices, depending on the context.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. EX Xxxxxx, division of Benchmark Investments, LLC (“Holder”), as registered owner of this Purchase Warrant, to TrovageneHealthcare Triangle, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ [________________] [DATE THAT IS ONE YEAR AFTER SIX MONTHS FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ [____________] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [____][1] shares of common stock of the Company, par value $0.0001 0.00001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [●] [110% OF THE PUBLIC OFFERING PRICE OF THE FIRM SHARES SOLD IN THE OFFERING] per Share [125% of the price of the Shares sold in the Offering]Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [●], 2021, the date on which the Registration Statement on Form S-1 (File No. 333-259180) of the Company was declared effective by the Securities and Exchange Commission (“Registration Statement”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid pursuant to that certain Underwriting Agreement by or and between Qilian International Holding Group Limited, a Cayman Islands company limited by shares (the “Company”), on behalf of Aegis Capital Corp. one hand, and Univest Securities, LLC (the “Holder”), on the other hand, dated [●], 2020 (the “Underwriting Agreement”), the Holder, as registered owner of this Purchase Warrant, to Trovagene, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS●], 20[__] (the “Commencement Exercise Date”), and at or before 5:00 p.m., Eastern time, [ ] on [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS●], 20[__] (the “Expiration Date”)Date”)[1], but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] such number of ordinary shares of common stock of the Company, par value $0.0001 0.00166667 per ordinary share (the “Ordinary Shares”) as equates to six percent (6%) of the Ordinary Shares sold in the Offering (the “Shares”), excluding any Ordinary Shares sold as result of the exercise by the underwriters of their over-allotment option, subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [●] per Ordinary Share [125(110% of the price of the Ordinary Shares sold in the Offering]); provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Ordinary Share and the number of Ordinary Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price as set forth above or the adjusted exercise priceprice as a result of the events set forth in Section 6 below, depending on the context. Capitalized terms not defined herein shall have the meaning ascribed to them in the Underwriting Agreement.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. XX Xxxxxx, division of Benchmark Investments, LLC (“Holder”), as registered owner of this Purchase Warrant, to TrovageneWarrant of Wytec International, Inc., a Delaware Nevada corporation (the “Company”), Holder is entitled, at any time or from time to time from [ [●] [DATE THAT IS ONE YEAR AFTER SIX MONTHS FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ [●] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [●] shares of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [●] per Share [125% of the price of the Shares sold in the Offering]Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [●], 2022, the date on which the Registration Statement on Form S-1 (File No. 333-261838) of the Company was declared effective by the Securities and Exchange Commission.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. (“Holder”), as registered owner of this Purchase Warrant, to TrovageneCurative Biotechnology, Inc., a Delaware Florida corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] beginning [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] ●], 2022 (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ ] on [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] ●], 2027 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [●] shares of common stock Common Stock of the Company, $0.0001 par value $0.0001 per share of Common Stock (the “SharesCommon Stock”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is not a day on which banking institutions are authorized by law to closeBusiness Day, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereinBusiness Day. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [●] per Share [125% share of the price of the Shares sold in the Offering]Common Stock; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share share of Common Stock and the number of Shares shares of Common Stock to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context, and the term “Business Day” shall mean a day other than a Saturday, Sunday or any other day which is a federal legal holiday in the United States or any day on which the Federal Reserve Bank of New York is authorized or required by law or other governmental action to close, provided that the Federal Reserve Bank of New York shall not be deemed to be authorized or obligated to be closed due to a “shelter in place,” “non-essential employee” or similar closure of physical location at the direction of any governmental authority if the bank’s electronic funds transfer systems (including for wire transfers) are open for use by customers on such day.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid pursuant to that certain Underwriting Agreement by or and between Northann Corp., a Nevada corporation (the “Company”), on behalf of Aegis the one hand, and Prime Executions, Inc. dba Freedom Capital Corp. Markets (the “Holder”), on the other hand, dated [●], 2023 (the “Underwriting Agreement”), the Holder, as registered owner of this Purchase Warrant, to Trovagene, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] ●], 2023 (the “Commencement Exercise Date”), and at or before 5:00 p.m., Eastern time, [ ] on [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] ●], 2028, (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] such number of shares of common stock of the Company, par value $0.0001 0.001 per share (“Common Stock”) as equates to six percent (6.0%) of the aggregate number of shares of Common Stock sold in the Offering (the “Shares”), including any Common Stock sold upon exercise of the over-allotment option, subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [●] per Share [125% share of Common Stock (which is equal to one hundred and ten percent (110%) of the price of the Shares shares of Common Stock sold in the Offering]); provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share share of Common Stock and the number of Shares shares of Common Stock to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price as set forth above or the adjusted exercise priceprice as a result of the events set forth in Section 6 below, depending on the context. Capitalized terms not defined herein shall have the meaning ascribed to them in the Underwriting Agreement.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. XX Xxxxxx, division of Benchmark Investments, LLC (“Holder”), as registered owner of this Purchase Warrant, to TrovageneWarrant Reborn Coffee, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER SIX MONTHS FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ ] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] shares of common stock of the Company, par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ ] per Share [125% of the price of the Shares sold in the Offering]Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [ ], 2022, the date on which the Registration Statement on Form S-1 (File No. 333- 261937) of the Company was declared effective by the Securities and Exchange Commission.

Purchase Warrant. THIS CERTIFIES THAT, pursuant to that certain Underwriting Agreement by and between VirTra, Inc., a Nevada corporation (the “Company”) and Boustead Securities, LLC (“Boustead”), as representative (the “Representative”) of the several underwriters listed in consideration of funds duly paid by Schedule A thereto (the “Underwriters”), dated [●], 2017 (the “Underwriting Agreement”), Boustead (in such capacity with its permitted successors or on behalf of Aegis Capital Corp. (assigns, the “Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] ●], 2017 (the “Commencement Exercise Date”), and at or before 5:00 p.m., Eastern time, [ ] [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] ●], 2022 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [●] shares of common stock of the Company, par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law or executive order to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period commencing on the date hereof and ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ ] per Share [125% (one hundred twenty percent (120.0%)) of the price of the Shares sold in the Offering]); provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. Any term not defined herein shall have the meaning ascribed thereto in the Underwriting Agreement. 1 NTD: 7% of shares issued in offering.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid the payment of $100.00 by or on behalf of Aegis Capital Corp. Corp or its assigns (“Holder”), as registered owner of this Purchase Warrant, ) to Trovagene1347 Property Insurance Holdings, Inc., a Delaware corporation (the “Company”), Holder and for other good and valuable consideration, Holder, as registered owner of this Purchase Warrant, is entitled, at any time or from time to time from [ [________________] [DATE THAT IS ONE YEAR AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ [____________] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [____] shares of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [___] per Share [125% of the price of the Shares sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. [ ](“Holder”), as registered owner of this Purchase Warrant, to TrovageneAnPac Bio-Medical Science Co., Inc.Ltd., a Delaware corporation business company incorporated under the laws of the British Virgin Islands (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS●], 20[19] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ ] [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] ●], 20[24], which will be the five-year anniversary of the effective date of the Company’s Form F-1 registration statement (File No.333-234408) (such date, the “Effective Date”) pursuant to which the Company’s securities are offered to the public (the “Offering”) (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [●] Class A ordinary shares of common stock of the CompanyCompany2, par value $0.0001 per share 0.01 (the “Shares”), in the form of American Depositary Shares (the “Warrant ADSs”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant, except as otherwise provided herein or with the Holder’s consent. This Purchase Warrant is initially exercisable at $[ ] [●]3 per Share [125% of the price of the Shares sold in the Offering]Warrant ADS; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share Warrant ADS and the number of Shares ADSs to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. _________ (“Holder”), as registered owner of this Purchase Warrant, to TrovageneAlliance MMA, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ [________________] [DATE THAT IS ONE YEAR AFTER SIX MONTHS FROM THE EFFECTIVE DATE OF PROSPECTUSTHE REGISTRATION STATEMENT] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ [____________] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE REGISTRATION STATEMENT] (the “”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [____] shares (the “Shares”) of common stock of the Company, par value $0.0001 0.001 per share (the “SharesCommon Stock”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [___] per Share [125165% of the price of the Shares sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context.. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Selling Agent Agreement, dated as of _________, 2016, by and between the Company and Network 1 Financial Services, Inc. (the “Selling Agent Agreement”)

Purchase Warrant. THIS CERTIFIES THAT, pursuant to that certain Selling Agency Agreement by and between Xspand Products Lab, Inc., a Nevada corporation (the “Company”) and Alexander Capital, L.P. (“Alexander Capital”), as representative (the “Representative”) of the several selling agents listed in consideration of funds duly paid by Schedule A thereto (the “Selling Agents”), dated [●], 2018 (the “Selling Agency Agreement”), Alexander Capital (in such capacity with its permitted successors or on behalf of Aegis Capital Corp. (assigns, the “Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [●], 20[ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] (the “Commencement Exercise Date”)) [THE DATE THAT IS 180 DAYS AFTER THE QUALIFICATION DATE OF THE OFFERING STATEMENT], and at or before 5:00 p.m., Eastern time, [●], 20[ ] [DATE THAT IS FIVE YEARS AFTER FROM THE QUALIFICATION DATE OF PROSPECTUSTHE OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [●] shares of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law or executive order to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period commencing on the date hereof and ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [●] per Share [125% (one hundred twenty percent (120.0%)) of the price of the Shares sold in the Offering]); provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. Any term not defined herein shall have the meaning ascribed thereto in the Selling Agency Agreement.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of [Aegis Capital Corp. Corp./ Chardan Capital Markets, LLC] (“Holder”), as registered owner of this Purchase Warrant, to TrovageneEyegate Pharmaceuticals, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ [________________] [DATE THAT IS ONE YEAR AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and until at or before 5:00 p.m., Eastern time, [ [____________] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [____] shares of common stock of the Company, par value $0.0001 0.01 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period commencing on the Effective Date and ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [___] per Share [125% of the price of the Shares Company’s common stock sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [ ], the date on which the Registration Statement on Form S-1 (File No. 333-197725) of the Company was declared effective by the Securities and Exchange Commission.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. (“HolderXX Xxxxxx, division of Benchmark Investments, LLC(“Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc.1847 Holdings LLC, a Delaware corporation limited liability company (the “Company”), Holder is entitled, at any time or from time to time from [ [________________] [DATE THAT IS ONE YEAR AFTER SIX MONTHS FROM THE DATE OF PROSPECTUSTHE COMMENCEMENT OF SALES OF THE PUBLIC SECURITIES IN THE INITIAL PUBLIC OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ [____________] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] [____]3 common shares of common stock of the Company, par value $0.0001 per share Company (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [●] per Share [125% of the price of the Shares sold in the Offering]OF THE PUBLIC OFFERING PRICE OF ONE UNIT SOLD IN THE OFFERING] per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [________], 2022, the date on which the Registration Statement on Form S-1 (File No. 333-259011) of the Company (“Registration Statement”) was declared effective by the Securities and Exchange Commission (“Commission”). This Purchase Warrant and the Shares exercisable hereby have been registered with the Commission on the Registration Statement and are thus freely tradeable.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. EX Xxxxxx, division of Benchmark Investments, LLC (“Holder”), as registered owner of this Purchase Warrant, to TrovageneEMulate Therapeutics, Inc., a Delaware Washington corporation (the “Company”), Holder is entitled, at any time or from time to time from [ [________________] [DATE THAT IS ONE YEAR AFTER SIX MONTHS FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ [____________] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [__] shares of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [__] per Share [125% of the price of the Shares sold in the Offering]Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [ ], 2022, the date on which the Registration Statement on Form S-1 (File No. 333-[●]) of the Company was declared effective by the Securities and Exchange Commission.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. EX Xxxxxx, division of Benchmark Investments, LLC (“Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc.Warrant Yoshiharu Global Co., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER SIX MONTHS FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ ] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] shares of Class A common stock of the Company, par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ ] per Share [125% of the price of the Shares sold in the Offering]Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [ ], 2022, the date on which the Registration Statement on Form S-1 (File No. 333- [ ]) of the Company was declared effective by the Securities and Exchange Commission.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of [Aegis Capital Corp. Corp./ Chardan Capital Markets, LLC] (“Holder”), as registered owner of this Purchase Warrant, to TrovageneEyegate Pharmaceuticals, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ [________________] [DATE THAT IS ONE YEAR AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and until at or before 5:00 p.m., Eastern time, [ [____________] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [____] shares of common stock of the Company, par value $0.0001 0.01 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period commencing on the Effective Date and ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [___] per Share [125% of the price of the Shares Company’s common stock sold in the OfferingOffering or 100% of the price of the Company’s common stock sold in the Offering to the Company’s insiders]; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [ ], the date on which the Registration Statement on Form S-1 (File No. 333-197725) of the Company was declared effective by the Securities and Exchange Commission.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. (“Holder”), as registered owner of this Purchase Warrant, to TrovageneRxxxxx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ [________________] [DATE THAT IS ONE YEAR AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ [____________] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [____] shares of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [___] per Share [125% of the public offering price of the Firm Shares sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [ ], the date on which the Registration Statement on Form S-1 (File No. 333-202924) of the Company was declared effective by the Securities and Exchange Commission.

Purchase Warrant. THIS CERTIFIES THAT, pursuant to that certain Underwriting Agreement by and between Flora Growth Corp., a company incorporated in consideration the Province of funds duly paid by Ontario (the “Company”) and Boustead Securities, LLC (“Boustead”), dated [●], 2021 (the “Underwriting Agreement”), Boustead (in such capacity with its permitted successors or on behalf of Aegis Capital Corp. (assigns, the “Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc., a Delaware corporation (the “Company”), Holder is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] ●], 20__ (the “Commencement Exercise Date”)) [THE DATE THAT THE WARRANT IS ISSUED], and at or before 5:00 p.m., Eastern time, [ ] [●], 20__ [DATE THAT IS FIVE YEARS AFTER FROM THE DATE OF PROSPECTUSON WHICH THE REGISTRATION STATEMENT IS DECLARED EFFECTIVE] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [●] shares of common stock Common Shares of the Company, without par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 5 hereof. If the Expiration Date is a day on which banking institutions are authorized by law or executive order to close, then this Purchase Warrant may be exercised on the next succeeding day which that is not such a day in accordance with the terms herein. During the period commencing on the date hereof and ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [●] per Share [(125% of the price of the Shares sold in the Offering]); provided, however, that upon the occurrence of any of the events specified in Section 6 5 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. Any term not defined herein shall have the meaning ascribed thereto in the Underwriting Agreement.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. Taglich Brothers, Inc. (“Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc.Air Industries Group, a Delaware Nevada corporation (the “Company”), Holder is entitled, at any time or from time to time from [ [________________] [DATE THAT IS ONE YEAR AFTER FROM THE DATE OF PROSPECTUSTHE COMMENCEMENT OF SALES OF THE OFFERING] (the “Commencement Date”), and until at or before 5:00 p.m., Eastern time, [ [____________] [DATE THAT IS FIVE YEARS AFTER FROM THE DATE OF PROSPECTUSTHE COMMENCEMENT OF SALES OF THE OFFERING] (the “”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [46,800] shares of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [11.25] per Share [125% of the price of the Shares sold in the OfferingOF THE OFFERING PRICE PER SHARE]; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean the date of the commencement of sales by the Company pursuant to a prospectus supplement filed by the Company in connection with a registered direct offering of shares of common stock of the Company pursuant to a Registration Statement on Form S-3 (File No. 333-191748) of the Company that was declared effective by the Securities and Exchange Commission on December 11, 2013.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. [__________] (“Holder”), as registered owner of this Purchase Warrant, to TrovageneAmmo, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ [●] [DATE THAT IS ONE YEAR AFTER HUNDRED EIGHTY (180) DAYS FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ [●] [DATE THAT IS FIVE (5) YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] shares of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 5 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [●] per Share [125% of the price of the Shares sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 5 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. This Warrant is being issued pursuant to the certain Underwriting Agreement (the “Underwriting Agreement”), dated [●], 2020, by and among the Company, the Holder and other underwriters named therein, providing for the public offering (the “Offering”) of shares of common stock, par value $0.001 per share, of the Company. The term “Effective Date” shall mean the effective date of the Registration Statement on Form S-1 (File No. 333- 248800). The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. Xxxxxx Xxxxx Securities, Inc. (“Holder”), as registered owner of this Purchase Warrant, to TrovageneRuthigen, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ [________________] [DATE THAT IS ONE YEAR AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and until at or before 5:00 p.m., Eastern time, [ [____________] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [____] shares of common stock of the Company, par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [___] per Share [125% of the public price of the Shares Company’s common stock and Series A Warrant combination sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [____], the date on which the Registration Statement on Form S-1 (File No. 333-190476) of the Company was declared effective by the Securities and Exchange Commission.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid pursuant to that certain Underwriting Agreement by or and between Hitek Global Inc., a Cayman Islands company(the “Company”), on behalf of Aegis Capital Corp. one hand, and Boustead Securities, LLC, on the other hand, dated [●], 20[__] (the “Underwriting Agreement”), Boustead Securities, LLC (“Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS●], 20[__] (the “Commencement Exercise Date”), and at or before 5:00 p.m., Eastern time, [ ] on [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS●], 20[__] (the “Expiration Date”)Date”)1, but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] such number of Class A ordinary shares of common stock of the Company, par value $0.0001 per ordinary share (the “Ordinary Shares”) as equates to six percent (6%) of the Ordinary Shares in the Offering (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [4.00] per Ordinary Share [125(100% of the price of the Ordinary Shares sold in the Offering]); provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Ordinary Share and the number of Ordinary Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price as set forth above or the adjusted exercise priceprice as a result of the events set forth in Section 6 below, depending on the context. Capitalized terms not defined herein shall have the meaning ascribed to them in the Underwriting Agreement.

Purchase Warrant. THIS CERTIFIES THAT, in consideration for good and valuable consideration, the receipt and sufficiency of funds duly paid by or on behalf of Aegis Capital Corp. which is hereby acknowledged, ______________ (“Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ [________________] [DATE THAT IS ONE YEAR AFTER HUNDRED EIGHTY (180) DAYS FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ [____________] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [____] shares (the “Shares”) of common stock of the Companystock, par value $0.0001 per share (the “SharesCommon Stock”), of Hoth Therapeutics, Inc., a Nevada corporation (the “Company”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized or required by law or executive order to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [●] per Share [equal to 125% of the price of the Shares shares sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. This Purchase Warrant is being issued in connection with a public offering of shares of Common Stock pursuant to the Company’s registration statement on Form S-1 (File No.: 333-227772) (the “Offering”). The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. As used herein, “Effective Date” means the date on which the Shares being sold in the Offering first become legally eligible for distribution to the public as determined in accordance with FINRA Conduct Rule 5110(a)(12).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. XX Xxxxxx, division of Benchmark Investments, LLC (“Holder”), as registered owner of this Purchase Warrant, to Trovagene, Onfolio Holdings Inc., a Delaware corporation (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries (the “Company”), Holder is entitled, at any time or from time to time from [ ] February 22, 2023 [DATE THAT IS ONE YEAR AFTER SIX MONTHS FROM THE DATE OF PROSPECTUSTHE COMMENCEMENT OF SALES OF THE PUBLIC SECURITIES IN THIS INITIAL PUBLIC OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ ] August 25, 2027 [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHIS OFFERING] (the “Expiration Date”), but not thereafter, to subscribe forrfoecr, purchase and receiveepivuer, in whole chinaswe haonlde or in part, up to [ ] shares of 82,6131 common stock stocks of the Company, par value $0.0001 per share Company (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ ] per Share [125% of the a price of the Shares sold in the Offering]; $5.50 per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price of $5.50 per Share (equal to 110% of the initial public offering price) or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean August 25, 2022, the date on which the Registration Statement on Form S•1 (File No. 333•264191) of the Company (“Registration Statement”) was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Kingswood Capital Corp. Markets, division of Benchmark Investments, Inc. (“Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc.ComSovereign Holding Corp., a Delaware Nevada corporation (the “Company”), Holder is entitled, at any time or from time to time from [ [________________] [DATE THAT IS ONE YEAR AFTER SIX MONTHS FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ [____________] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [____] shares of common stock of the Company, par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [___] per Share [125110% of the public offering price of the Firm Shares sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [ ], the date on which the Registration Statement on Form S-1 (File No. 333-248490) of the Company was declared effective by the Securities and Exchange Commission.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf the payment of $100.00 and for other good and value consideration, Aegis Capital Corp. or its assigns (“Holder”), as registered owner of this Purchase Warrant, to TrovageneNephroGenex, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ [________________] [DATE THAT IS ONE YEAR AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ [____________] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [____] shares of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [___] per Share [125% of the price of the Shares sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean the date on which the Registration Statement on Form S-1 (File No. 333-193023) of the Company was declared effective by the Securities and Exchange Commission.

Purchase Warrant. THIS CERTIFIES THAT, pursuant to that certain Underwriting Agreement by and between., Wah Fu Education Group Limited, a British Virgin Islands company (the “Company”) and Network 1 Securities, Inc. (“Network 1”), dated [●], 2018 (the “Underwriting Agreement”), Network 1 (in consideration of funds duly paid by such capacity with its permitted successors or on behalf of Aegis Capital Corp. (assigns, the “Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS●], 20[__] (the “Commencement Exercise Date”)) [THE DATE THAT IS 180 DAYS AFTER THE EFFECTIVE DATE OF THE REGISTRATION STATEMENT], and at or before 5:00 p.m., Eastern time, [●], 20[ ] [DATE THAT IS FIVE THREE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [●] shares of common stock Ordinary Shares of the Company, par value $0.0001 0.01 per share (the “Shares”), subject to adjustment as provided in Section 6 5 hereof. If the Expiration Date is a day on which banking institutions are authorized by law or executive order to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period commencing on the date hereof and ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [●] per Share [(125% of the price of the Shares sold in the Offering]); provided, however, that upon the occurrence of any of the events specified in Section 6 5 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. Any term not defined herein shall have the meaning ascribed thereto in the Underwriting Agreement.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid pursuant to that certain Underwriting Agreement by or on behalf of Aegis Capital Corp. (“Holder”), as registered owner of this Purchase Warrant, to Trovageneand between Elevai Labs, Inc., a Delaware corporation (the “Company”), Holder on the one hand, and Univest Securities, LLC (the “Holder”), on the other hand, dated [●], 2023 (the “Underwriting Agreement”), the Holder, as registered owner of this Purchase Warrant, is entitled, at any time or from time to time from [ ] the date that is six months from [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] ●], 2023 (the “Commencement Exercise Date”), and at or before 5:00 p.m., Eastern time, [ ] on [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] ●], 2028, (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] such number of shares of common stock of the Company, par value $0.0001 per share (“Common Stock”) as equates to five percent (5.0%) of the aggregate number of shares of Common Stock sold in the Offering (the “Shares”), including any Common Stock sold upon exercise of the over-allotment option, subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [●] per Share [125% share of Common Stock (which is equal to one hundred percent (100%) of the price of the Shares shares of Common Stock sold in the Offering]); provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share share of Common Stock and the number of Shares shares of Common Stock to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price as set forth above or the adjusted exercise priceprice as a result of the events set forth in Section 6 below, depending on the context. Capitalized terms not defined herein shall have the meaning ascribed to them in the Underwriting Agreement. 1 Five (5) years from the commencement of sales of the public offering.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. Feltl and Company, Inc. (“Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc.BioLight Life Sciences Ltd., a Delaware corporation an Israeli company (the “Company”), Holder is entitled, at any time or from time to time from [ [________________] [DATE THAT IS ONE YEAR AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and until at or before 5:00 p.m., Eastern time, [ [_________] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [____] ordinary shares of common stock (the “Shares”) of the Company, par value $0.0001 NIS 2.5 per share (the “Ordinary Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [____] per Share [equal to 125% of the price higher of the Shares sold in Company’s share closing price on the OfferingTel Aviv Stock Exchange a day before the initial public offering and the initial public offering price per share]; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [ ], the date on which the Registration Statement on Form F-1 (File No. 333-209454) of the Company was declared effective by the Securities and Exchange Commission.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid pursuant to that certain Underwriting Agreement by or and between Qilian International Holding Group Limited, a Cayman Islands company limited by shares (the “Company”), on behalf of Aegis Capital Corp. one hand, and Univest Securities, LLC (the “Holder”), on the other hand, dated [●], 2019 (the “Underwriting Agreement”), the Holder, as registered owner of this Purchase Warrant, to Trovagene, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS●], 20[__] (the “Commencement Exercise Date”), and at or before 5:00 p.m., Eastern time, [ ] on [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS●], 20[__] (the “Expiration Date”)Date”)[1], but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] such number of ordinary shares of common stock of the Company, par value $0.0001 0.001 per ordinary share (the “Ordinary Shares”) as equates to six percent (6%) of the Ordinary Shares sold in the Offering (the “Shares”), excluding any Ordinary Shares sold as result of the exercise by the underwriters of their over-allotment option, subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [●] per Ordinary Share [125(110% of the price of the Ordinary Shares sold in the Offering]); provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Ordinary Share and the number of Ordinary Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price as set forth above or the adjusted exercise priceprice as a result of the events set forth in Section 6 below, depending on the context. Capitalized terms not defined herein shall have the meaning ascribed to them in the Underwriting Agreement.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. [__________] (“Holder”), as registered owner of this Purchase Warrant, to TrovageneCo-Diagnostics, Inc., a Delaware Utah corporation (the “Company”), Holder is entitled, at any time or from time to time from [ [_________________] [DATE THAT IS ONE (1) YEAR AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ [_______________] [DATE THAT IS FIVE (5) YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [_______________] shares of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 5 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [_____________] per Share [125120% of the price of the Shares sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 5 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. This Warrant is being issued pursuant to the certain Underwriting Agreement (the “Underwriting Agreement”), dated ______, 2017, by and among the Company, the Holder and other underwriters named therein, providing for the public offering (the “Offering”) of shares of common stock, par value $0.001 per share, of the Company. The term “Effective Date” shall mean the effective date of the Offering. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. __________ (“Holder”), as registered owner of this Common Stock Purchase Warrant (this “Purchase Warrant”), to TrovageneAcurx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] ___, [DATE THAT IS ONE YEAR AFTER 180 DAYS FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ ] ____, 202__ [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] shares (the “Shares”) of common stock of the Company, par value $0.0001 0.001 per share (the “SharesCommon Stock”), subject to adjustment as provided in Section 6 5 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ ] __ per Share [125% of the price of the Shares sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 5 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. This Purchase Warrant is being issued pursuant to the certain Underwriting Agreement (the “Underwriting Agreement”), dated ___, 2021, by and among the Company, the Representative and other underwriters named therein, providing for the public offering (the “Offering”) of shares of Common Stock. The term “Effective Date” shall mean the effective date of the Registration Statement on Form S-1 (File No. 333-___). The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. Initially capitalized terms not otherwise defined herein shall have the meanings given to those terms in the Underwriting Agreement.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. [●] (“Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc., China Internet Nationwide Financial Services Inc. a Delaware corporation British Virgin Island (the “Company”), Holder is entitled, at any time or from time to time from [ [●] [DATE THAT IS ONE YEAR AFTER EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [●] [ ] [DATE THAT IS FIVE TWO YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING ] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] such number of ordinary shares of common stock of the Company, par value $0.0001 0.001 per share as equates to six and one half percent (6.5%) of the gross amount raised during the Offering divided by $5.00, being the subscription price per ordinary share in the Offering (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which U.S. banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ ] 6.00 per Share (the “Exercise Price”) [125120% of the price of the Shares sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or include the adjusted exercise priceprice as a result of the events in Section 6 below, depending on the context.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. XX Xxxxxx, division of Benchmark Investments, LLC (“Holder”), as registered owner of this Purchase Warrant, to Trovagene, Onfolio Holdings Inc., a Delaware corporation (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries (the “Company”), Holder is entitled, at any time or from time to time from [ ] _______, 2022 [DATE THAT IS ONE YEAR AFTER SIX MONTHS FROM THE DATE OF PROSPECTUSTHE COMMENCEMENT OF SALES OF THE PUBLIC SECURITIES IN THIS INITIAL PUBLIC OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ ] _______, 2027 [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHIS OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] shares of [●]1 common stock stocks of the Company, par value $0.0001 per share Company (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ ] per Share [125% of the a price of the Shares sold in the Offering]$___ per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price of $____ per Share (equal to 110% of the initial public offering price) or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean ___________, 2022, the date on which the Registration Statement on Form S-1 (File No. 333-264191) of the Company (“Registration Statement”) was declared effective by the Securities and Exchange Commission (the “Commission”). This Purchase Warrant and the Shares exercisable hereby have been registered with the Commission on the Registration Statement and are thus freely tradeable.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. (“Holder”), as registered owner of this Purchase Warrant, to TrovageneMaris-Tech Ltd., Inc., a Delaware corporation an Israeli company (the “Company”), Holder is entitled, at any time or from time to time from [ ] beginning [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] ●], 2021 (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ ] on [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] ●], 2026 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [●] ordinary shares of common stock of the Company, no par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is not a day on which banking institutions are authorized by law to closeBusiness Day, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereinBusiness Day. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [●] per Share [125% of the price of the Shares sold in the Offering]Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context, and the term “Business Day” shall mean a day other than a Saturday, Sunday or any other day which is a federal legal holiday in the United States or any day on which the Federal Reserve Bank of New York is authorized or required by law or other governmental action to close, provided that the Federal Reserve Bank of New York shall not be deemed to be authorized or obligated to be closed due to a “shelter in place,” “non-essential employee” or similar closure of physical location at the direction of any governmental authority if the bank’s electronic funds transfer systems (including for wire transfers) are open for use by customers on such day.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. [●] (“Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc., China Internet Nationwide Financial Services Inc. a Delaware corporation British Virgin Island (the “Company”), Holder is entitled, at any time or from time to time from [ [●] [DATE THAT IS ONE YEAR AFTER EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [●] [ ] [DATE THAT IS FIVE TWO YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING ] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] such number of ordinary shares of common stock of the Company, par value $0.0001 0.001 per share as equates to four and one half percent (4.5%) of the gross amount raised during the Offering divided by $10.00, being the subscription price per ordinary share in the Offering (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which U.S. banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ ] 12.00 per Share (the “Exercise Price”) [125120% of the price of the Shares sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or include the adjusted exercise priceprice as a result of the events in Section 6 below, depending on the context.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. Westpark Capital, Inc. (“Holder”), as registered owner of this Purchase Warrant, to TrovageneWarrant of Opti-Harvest, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ [________________] [DATE THAT IS ONE YEAR AFTER SIX MONTHS FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ [____________] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [__] shares of common stock of the Company, par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [__] per Share [125% of the price of the Shares sold in the Offering]Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [ ], 2022, the date on which the Registration Statement on Form S-1 (File No. 333-[●]) of the Company was declared effective by the Securities and Exchange Commission.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis [Spartan Capital Corp. Securities, LLC][X.X. Xxxxxxxx & Co., Inc.] (“Holder”), as registered owner of this Purchase Warrant, to Trovagene, Xxxxxxx Inc., a Delaware corporation (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] _______, 2023 (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ ] [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] _______, 2027 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ an aggregate of [__] shares of common stock of the Companyshares, par value $0.0001 0.00001 per share (the “Shares”)) of the Company’s common stock, subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ ] per Share [125% of the a price of the Shares sold in the Offering]$____ per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price of $____ per Share (equal to 110% of the initial public offering price) or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean ___________, 2023, the date on which the Registration Statement on Form S-1, as amended (File No. 333-267907) of the Company was declared effective by the Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. _________ (“Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc.Long Island Iced Tea Corp., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ [________________] [DATE THAT IS ONE YEAR AFTER SIX MONTHS FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ [____________] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [____] shares (the “Shares”) of common stock of the Company, par value $0.0001 per share (the “SharesCommon Stock”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [___] per Share [125110% of the price of the Shares sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context.. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Underwriting Agreement, dated as of [●], 2016, by and between the Company and Network 1 Financial Services, Inc.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. (“HolderAegis”), as registered owner of this Purchase Warrant, to TrovageneStemline Therapeutics, Inc., a Delaware corporation (the “Company”), Holder Aegis (Aegis or the registered holder of this Purchase Warrant by virtue of a permitted assignment or transfer under Section 3, the “Holder”) is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUSEFFECTIVENESS] (the “Commencement Date”), and until at or before 5:00 p.m., Eastern time, [ ] [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUSEFFECTIVENESS] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] shares of common stock of the Company, par value $0.0001 per share (the “Shares”)share, subject to adjustment as provided in Section 6 hereofhereof (the “Shares”). If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the Purchase Warrant. This Purchase Warrant is initially exercisable at $[ ] per Share [125150% of the price of the Shares Company’s common stock sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. EX Xxxxxx, division of Benchmark Investments, LLC. (“Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc.CW Petroleum Corp, a Delaware Wyoming corporation (the “Company”), Holder is entitled, at any time or from time to time from [ [________________] [DATE THAT IS ONE YEAR AFTER SIX MONTHS FROM THE DATE OF PROSPECTUSTHE COMMENCEMENT OF SALES OF THE PUBLIC SECURITIES IN THE INITIAL PUBLIC OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ [____________] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] shares of [____]4 common stock of the Company, par value $0.0001 per share Company (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [●] [100% OF THE PUBLIC OFFERING PRICE OF ONE UNIT SOLD IN THE OFFERING] per Share [125% of the price of the Shares sold in the Offering]Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [________], 2022, the date on which the Registration Statement on Form S-1 (File No. 333-[_______]) of the Company (“Registration Statement”) was declared effective by the Securities and Exchange Commission (“Commission”). This Purchase Warrant and the Shares exercisable hereby have been registered with the Commission on the Registration Statement and are thus freely tradeable.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. [●] (“Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc.PROFICIENT ALPHA ACQUISITION CORP., a Delaware Nevada corporation (the “Company”), Holder is entitled, at any time or from time to time upon the later of the consummation of a Business Combination or one-year from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] the Effective Date (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ ] [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] on the earlier of (i) the liquidation of the Company’s Trust Account (as described in the Company’s registration statement on Form S-1 (File No. 333-231084) (the “Registration Statement”) pursuant to which the Company’s securities are offered for sale to the public in the Company’s initial public offering (“Offering”) in the event the Company has not completed a Business Combination within the required time periods and (ii) five years from the effective date (“Effective Date”) of the Registration Statement (“Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [●] shares of Company common stock of the Company, par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant, except as otherwise provided herein or with the Holder’s consent. This Purchase Warrant is initially exercisable at $[ ] 12.00 per Share [125% of the price of the Shares sold in the Offering]Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context.. [1] [Insert 8% of shares sold in offering]

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. XX Xxxxxx, division of Benchmark Investments, LLC (“Holder”), as registered owner of this Purchase WarrantWarrant issued by Guardforce AI Co., to Trovagene, Inc.Limited, a Delaware corporation Cayman Islands company (the “Company”), Holder is entitled, at any time or from time to time from [ [●] [DATE THAT IS ONE YEAR AFTER SIX MONTHS FROM THE DATE OF PROSPECTUSCOMMENCEMENT OF SALES OF THE OFFERING] (the “Commencement Date”), and until at or before 5:00 p.m., Eastern time, [ [●] [DATE THAT IS FIVE FOUR AND A HALF-YEARS AFTER DATE OF PROSPECTUSFROM THE COMMENCEMENT DATE] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [●] shares of common stock Ordinary Shares of the Company, par value $0.0001 0.003 per share (the “Ordinary Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [●] per Share [125% of the price of the Shares sold in the Offering]Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Ordinary Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [●], 2021, the date on which the Registration Statement on Form F-1 (File No. 333-[●]) of the Company was declared effective by the Securities and Exchange Commission.

Purchase Warrant. THIS CERTIFIES THAT, pursuant to that certain Underwriting Agreement by and between., FOTV Media Networks Inc., a Delaware corporation (the “Company”) and Monarch Bay Securities, LLC (“MBS”), as Representative of the several underwriters, dated August [●], 2016 (the “Underwriting Agreement”), MBS (in consideration of funds duly paid by such capacity with its permitted successors or on behalf of Aegis Capital Corp. (assigns, the “Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] ●], 2016 (the “Commencement Exercise Date”)) [THE EFFECTIVE DATE OF THE REGISTRATION STATEMENT], and at or before 5:00 p.m., Eastern time, [ ] [●], 2021 [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [●] shares [NUMBER OF SHARES EQUAL TO 3% OF SHARES SOLD IN THE IPO] of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law or executive order to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period commencing on the date hereof and ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [10.00] per Share [125(125.0% of the price of the Shares sold in the Offering]); provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. Any term not defined herein shall have the meaning ascribed thereto in the Underwriting Agreement.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. EX Xxxxxx, division of Benchmark Investments, LLC (“Holder”), as registered owner of this Purchase Warrant, to TrovageneWarrant of Opti-Harvest, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ [________________] [DATE THAT IS ONE YEAR AFTER SIX MONTHS FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ [____________] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [__] shares of common stock of the Company, par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [__] per Share [125% of the price of the Shares sold in the Offering]Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [ ], 2022, the date on which the Registration Statement on Form S-1 (File No. 333-261990) of the Company was declared effective by the Securities and Exchange Commission.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. Viewtrade Securities, Inc. (“Holder”), as registered owner of this Purchase Warrant, to Trovagene, The Future Education Group Inc., a Delaware Nevada corporation (the “Company”), Holder is entitled, at any time or from time to time from [ [_] [DATE THAT IS ONE YEAR AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ [_] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [_] shares of Class A common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [_] per Share [125110% of the price of the Shares sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. (“Holder”), as registered owner of this Purchase Warrant, to TrovageneGenprex, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS180 DAYS FROM THE EFFECTIVE DATE] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ ] [DATE THAT IS FIVE YEARS AFTER FROM THE CLOSING DATE OF PROSPECTUSTHE OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] shares (the “Warrant Shares”) of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ ] $ per Warrant Share [(125% of the price of the Shares shares of common stock sold in the proposed initial public offering of Shares (the “Offering]”); provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Warrant Share and the number of Warrant Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean the date that the Company’s Registration Statement on Form S-1 (File No. 333-219386) is declared effective under the Securities Act of 1933, as amended (the “Securities Act”) by the U.S. Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid pursuant to that certain Underwriting Agreement by or and between 3 E NETWORK TECHNOLOGY GROUP LIMITED, a British Virgin Islands company (the “Company”), on behalf of Aegis Capital Corp. one hand, and Boustead Securities, LLC (the “Holder”), on the other hand, dated [ ], 2024 (the “Underwriting Agreement”), the Holder, as registered owner of this Purchase Warrant, to Trovagene, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] ], 2024 (the “Commencement Exercise Date”), and at or before 5:00 p.m., Eastern time, on [ ] [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] ], 2027 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] Class A ordinary shares of common stock (the “Shares”) of the Company, par value $0.0001 per ordinary share (the “Ordinary Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law or executive order to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ ] per Ordinary Share [125(100% of the per share public offering price of the Shares sold in initial public offering pursuant to the Underwriting Agreement (the “Offering]”)); provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Ordinary Share and the number of Ordinary Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price as set forth above or the adjusted exercise priceprice as a result of the events set forth in Section 6 hereof, depending on the context. Capitalized terms not defined herein shall have the meaning ascribed to them in the Underwriting Agreement.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. BXXXXXXX CAPITAL, LLC, LLC (“Holder”), as registered owner of this Purchase Warrant, to Trovagene, Cingulate Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ [________________] [DATE THAT IS ONE YEAR AFTER SIX MONTHS FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ [____________] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] [__]1 shares of common stock of the Company, par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ ] [__]2 per Share [125% of the price of the Shares sold in the Offering]Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [ ], 2023, the date on which the Registration Statement on Form S-1 (File No. 333-273405) of the Company was declared effective by the Securities and Exchange Commission.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by for value received, CRT Capital Group LLC or on behalf of Aegis Capital Corp. its assigns (“Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] (the “Commencement Date”), and until at or before 5:00 p.m., Eastern time, [ ] [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] shares of common stock of Adamis Pharmaceuticals Corporation, a Delaware corporation (the “Company”), par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 5 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ ] per Share [125% of the price of the Shares sold in the Offering]Share; provided, howeverhowever , that upon the occurrence of any of the events specified in Section 6 5 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean November __, 2013, the date on which the Registration Statement on Form S-1 (File No. 333-192372) of the Company was declared effective by the Securities and Exchange Commission.

Purchase Warrant. THIS CERTIFIES THATCLASS A ORDINARY SHARES PURCHASE WARRANT (this “Purchase Warrant”) certifies that, pursuant to that certain Underwriting Agreement by and between Tungray Technologies Inc, a Cayman Islands exempted company (the “Company”) and US Tiger Securities, Inc. (“US Tiger”), dated [●], 2024 (the “Underwriting Agreement”), US Tiger Securities, Inc. (in consideration of funds duly paid by such capacity with its permitted successors or on behalf of Aegis Capital Corp. (assigns, the “Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] ●], 2024 (the “Commencement Exercise Date”), and at or before 5:00 p.m., Eastern time, [ ] [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] ●], 2029 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [●] shares of common stock Class A Ordinary Shares of the Company, par value $US$0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 5 hereof. If the Expiration Date is a day on which banking institutions are authorized by law or executive order to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period commencing on the date hereof and ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ US$[●] per Share [125(120% of the price of the Shares sold in the offering pursuant to the Registration Statement (the “Offering]”)); provided, however, that upon the occurrence of any of the events specified in Section 6 5 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. Any term not defined herein shall have the meaning ascribed thereto in the Underwriting Agreement.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid pursuant to that certain Underwriting Agreement by or and between Hitek Global Inc., a Cayman Islands company(the “Company”), on behalf of Aegis Capital Corp. one hand, and Boustead Securities, LLC, on the other hand, dated [●], 20[__] (the “Underwriting Agreement”), Boustead Securities, LLC (“Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS●], 20[__] (the “Commencement Exercise Date”), and at or before 5:00 p.m., Eastern time, [ ] on [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS●], 20[__] (the “Expiration Date”)Date”)1, but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] such number of Class A ordinary shares of common stock of the Company, par value $0.0001 per ordinary share (the “Ordinary Shares”) as equates to six percent (6%) of the Ordinary Shares in the Offering (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [5.00] per Ordinary Share [125(100% of the price of the Ordinary Shares sold in the Offering]); provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Ordinary Share and the number of Ordinary Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price as set forth above or the adjusted exercise priceprice as a result of the events set forth in Section 6 below, depending on the context. Capitalized terms not defined herein shall have the meaning ascribed to them in the Underwriting Agreement.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. [Xxxxxx Xxxxxx & Co., LLC/ Feltl and Company, Inc./Neidiger, Tucker, Bruner, Inc.] (“Holder”), as registered owner of this Purchase Warrant, to TrovageneSensus Healthcare, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ [________________] [DATE THAT IS ONE YEAR AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and UNTIL at or before 5:00 p.m., Eastern time, [ [____________] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [____] shares of common stock of the Company, par value $0.0001 0.01 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period commencing on the Effective Date and ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [___] per Share [125% of the price of the Shares sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [ ], the date of that certain Underwriting Agreement, by and between the Company and Xxxxxx Xxxxxx & Co., LLC, as representative of the underwriters named therein (the “Underwriting Agreement”).

Purchase Warrant. THIS CERTIFIES THAT, pursuant to that certain Underwriting Agreement by and between Gelteq Limited, an Australian public limited company limited to shares (the “Company”) and Boustead Securities, LLC (“Boustead”), dated [ ], 2023 (the “Underwriting Agreement”), Boustead (in consideration of funds duly paid by such capacity with its permitted successors or on behalf of Aegis Capital Corp. (assigns, the “Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc., a Delaware corporation (the “Company”), Holder is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] ], 2023 (the “Commencement Issuance Date”), and at or before 5:00 p.m., Eastern time, [ ] [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] *], 2028 (the “Expiration Date,”) which such date is five (5) years from the commencement of the sales of the Ordinary Shares in connection with the initial public offering contemplated by the Underwriting Agreement (the “Offering”) under the registration statement on Form F-1 (Registration No. 333-[ ]) of the Company (the “Registration Statement”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] shares of common stock Ordinary Shares of the Company, no par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 5 hereof. This Purchase Warrant is not exercisable or convertible for more than five years from the commencement of sales of Ordinary Shares in the Offering. If the Expiration Date is a day on which banking institutions are authorized by law or executive order to close, then this Purchase Warrant may be exercised on the next succeeding day which that is not such a day in accordance with the terms herein. During the period commencing on the date hereof and ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ ] per Share [125(100% of the price of the Shares sold in the Offering]); provided, however, that upon the occurrence of any of the events specified in Section 6 5 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. Any term not defined herein shall have the meaning ascribed thereto in the Underwriting Agreement.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. [__________] (“Holder”), as registered owner of this Purchase Warrant, to TrovageneHxxxxxx Jxxxx Laboratories, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ [______________] [DATE THAT IS ONE YEAR AFTER 180 DAYS FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ [______________] [DATE THAT IS FIVE (5) YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [_____________] shares of common stock of the Company, par value $0.0001 0.00001 per share (the “Shares”), subject to adjustment as provided in Section 6 5 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [_______________] per Share [125120% of the price of the Shares sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 5 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. This Warrant is being issued pursuant to the certain Placement Agency Agreement (the “Placement Agency Agreement”), dated June __, 2019, by and among the Company, the Holder and other selected dealers named therein, providing for the public offering (the “Offering”) of shares of common stock, par value $0.00001per share, of the Company. The term “Effective Date” shall mean the effective date of the Offering. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context.

Purchase Warrant. THIS CERTIFIES THATORDINARY SHARES PURCHASE WARRANT (this “Purchase Warrant”) certifies that, pursuant to that certain Underwriting Agreement by and between Mobile-health Network Solutions, a Cayman Islands exempted company (the “Company”) and Network 1 Financial Securities, Inc. (“Network 1”), dated [ ], 202_ (the “Underwriting Agreement”), Network 1 (in consideration of funds duly paid by such capacity with its permitted successors or on behalf of Aegis Capital Corp. (assigns, the “Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] ], 202_ (the “Commencement Date”)Exercise Date”)3, and at or before 5:00 p.m., Eastern time, [ ] [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] ], 202_2 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] shares of common stock Ordinary Shares of the Company, par value $0.0001 0.001 per share (the “Shares”)Shares”)4, subject to adjustment as provided in Section 6 5 hereof. If the Expiration Date is a day on which banking institutions are authorized by law or executive order to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period commencing on the date hereof and ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ ] per Share [125(140% of the price of the Shares sold in the Offering]); provided, however, that upon the occurrence of any of the events specified in Section 6 5 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. Any term not defined herein shall have the meaning ascribed thereto in the Underwriting Agreement. [The Purchase Warrant is redeemable.]

Purchase Warrant. THIS CERTIFIES THAT, pursuant to that certain Underwriting Agreement by and between RVeloCITY Inc., a company incorporated in consideration the State of funds duly paid by Delaware (the “Company”), and Boustead Securities, LLC (“Boustead”), dated [●], 2023 (the “Underwriting Agreement”), Bxxxxxxx (in such capacity with its permitted successors or on behalf of Aegis Capital Corp. (assigns, the “Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc., a Delaware corporation (the “Company”), Holder is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] ●], 20__ (the “Commencement Exercise Date”)) [THE DATE THAT THE WARRANT IS ISSUED], and at or before 5:00 p.m., Eastern time, [ ] [●], 20__ [DATE THAT IS FIVE YEARS AFTER FROM THE DATE OF PROSPECTUSON WHICH THE REGISTRATION STATEMENT IS DECLARED EFFECTIVE] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [●] shares of common stock Class A Common Shares of the Company, without par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 5 hereof. If the Expiration Date is a day on which banking institutions are authorized by law or executive order to close, then this Purchase Warrant may be exercised on the next succeeding day which that is not such a day in accordance with the terms herein. During the period commencing on the date hereof and ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [●] per Share [125% of (the price of the Shares sold in the Offering]); provided, however, that upon the occurrence of any of the events specified in Section 6 5 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. Any term not defined herein shall have the meaning ascribed thereto in the Underwriting Agreement.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. WallachBeth Capital, LLC or its assigns (“Holder”), as registered owner of this Purchase Warrant, to TrovageneGuardion Health Services, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] ●], 2020 (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ ] [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] ●], 2024 (the “”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [●] shares (the “Shares”) of common stock of the Company, par value $0.0001 0.001 per share (the “Shares”)share, subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant except as otherwise provided herein or with the Purchase WarrantHolder’s consent. This Purchase Warrant is initially exercisable at $[ [●] per Share [125% of the price of the Shares sold in the Offering]Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. This Purchase Warrant is being issued pursuant to that certain Underwriting Agreement, dated [●], 2019 (the “Agreement”), between the Company and, on behalf of the Underwriters named on Schedule 1 thereto, WallachBeth Capital, LLC (“WallachBeth”). The Company’s offering contemplated by the Agreement is referred to herein as the “Offering.”

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. WallachBeth Capital, LLC or its assigns (“Holder”), as registered owner of this Purchase Warrant, to Trovagene, SeqLL Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] ●], 2020 (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ ] [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] ●], 2024 (the “”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [●] shares (the “Shares”) of common stock of the Company, par value $0.0001 0.00001 per share (the “Shares”)share, subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant except as otherwise provided herein or with the Purchase WarrantHolder’s consent. This Purchase Warrant is initially exercisable at $[ [●] per Share [125% of the price of the Shares sold in the Offering]Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. This Purchase Warrant is being issued pursuant to that certain Underwriting Agreement, dated [●], 2019 (the “Agreement”), between the Company and, on behalf of the Underwriters named on Schedule 1 thereto, WallachBeth Capital, LLC (“WallachBeth”). The Company’s offering contemplated by the Agreement is referred to herein as the “Offering.”

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. (“Holder”), as registered owner of this Purchase Warrant, to TrovageneAspenBio Pharma, Inc., a Delaware Colorado corporation (the “Company”), Holder is entitled, at any time or from time to time from [ [________________] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUSEFFECTIVE DATE] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ [____________] [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUSEFFECTIVE DATE] (the “”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [____] shares of common stock of the Company, no par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [___] per Share [125% of the price of the Shares sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. The Benchmark Company LLC or its assigns (“Holder”), as registered owner of this Purchase Warrant, to TrovageneYayYo, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] November [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] ●], 2018 (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ ] November [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] ●], 2023 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [●] shares (the “Shares”) of common stock of the Company, par value $0.0001 0.000001 per share (the “Shares”)share, subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant except as otherwise provided herein or with the Purchase WarrantHolder’s consent. This Purchase Warrant is initially exercisable at $[ [●] per Share [125% of the price of the Shares sold in the Offering]Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. This Purchase Warrant is being issued pursuant to that certain Underwriting Agreement, dated November [●], 2018 (the “Agreement”), between the Company and, on behalf of the Underwriters named on Schedule 1 thereto, The Benchmark Company LLC (“Benchmark”). The Company’s offering contemplated by the Agreement is referred to herein as the “Offering.”

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. (“Holder”), as registered owner of this Purchase Warrant, to TrovageneJP Outfitters, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ beginning [●] , 2023 [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUSSIX MONTHS FROM THE ISSUANCE DATE] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ ] on [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] ●], 2028 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [●] shares of common stock of the Company, par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is not a day on which banking institutions are authorized by law to closeBusiness Day, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereinBusiness Day. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [●] per Share [125% of the price of the Shares sold in the OfferingPXX price]; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context, and the term “Business Day” shall mean a day other than a Saturday, Sunday or any other day which is a federal legal holiday in the United States or any day on which the Federal Reserve Bank of New York is authorized or required by law or other governmental action to close, provided that the Federal Reserve Bank of New York shall not be deemed to be authorized or obligated to be closed due to a “shelter in place,” “non-essential employee” or similar closure of physical location at the direction of any governmental authority if the bank’s electronic funds transfer systems (including for wire transfers) are open for use by customers on such day.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid pursuant to that certain Underwriting Agreement by or and between Chanson International Holding, a Cayman Islands company limited by shares (the “Company”), on behalf of Aegis Capital Corp. one hand, and Univest Securities, LLC (the “Holder”), on the other hand, dated [ ● ], 2021 (the “Underwriting Agreement”), the Holder, as registered owner of this Purchase Warrant, to Trovagene, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] ● ], 2021 (the “Commencement Exercise Date”), and at or before 5:00 p.m., Eastern time, on [ ] [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] ● ], 2026, (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] such number of Class A ordinary shares of common stock of the Company, par value $0.0001 0.001 per share (the “Ordinary Shares”) as equates to four percent (4%) of the Ordinary Shares sold in the Offering (the “Shares”), excluding any Ordinary Shares sold as result of the exercise by the underwriter of its over-allotment option, subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ ● ] per Ordinary Share [(125% %) of the price of the Ordinary Shares sold in the Offering]); provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Ordinary Share and the number of Ordinary Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price as set forth above or the adjusted exercise priceprice as a result of the events set forth in Section 6 below, depending on the context. Capitalized terms not defined herein shall have the meaning ascribed to them in the Underwriting Agreement.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. (the “Holder”), as registered owner of this warrant to purchase shares of Common Stock (as defined below (the “Purchase Warrant”), to Trovagene, Serve Robotics Inc., a Delaware corporation (the “Company”), the Holder is entitled, at any time or from time to time from [ ] beginning [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] ●], 20242 (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ ] on [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] ●], 20293 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [●] shares (the “Shares”) of common stock of the Company, par value $0.0001 per share (the “SharesCommon Stock”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is not a day on which banking institutions are authorized by law to closeBusiness Day, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms hereinBusiness Day. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ ] [●]4 per Share [125% of the price of the Shares sold in the Offering]Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context, and the term “Business Day” shall mean a day other than a Saturday, Sunday or any other day which is a federal legal holiday in the United States or any day on which the Federal Reserve Bank of New York is authorized or required by law or other governmental action to close, provided that the Federal Reserve Bank of New York shall not be deemed to be authorized or obligated to be closed due to a “shelter in place,” “non-essential employee” or similar closure of physical location at the direction of any governmental authority if the bank’s electronic funds transfer systems (including for wire transfers) are open for use by customers on such day. 2 INSERT DATE 180 DAYS AFTER EFFECTIVE DATE. 3 INSERT DATE 5 YEARS AFTER EFFECTIVE DATE. 4 INSERT 125% of PUBLIC OFFERING PRICE PER SHARE.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. Westpark Capital, Inc. (“Holder”), as registered owner of this Purchase Warrant, to TrovageneWarrant of Opti-Harvest, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ [________________] [DATE THAT IS ONE YEAR AFTER SIX MONTHS FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ [____________] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [__] shares of common stock of the Company, par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ ] 4.15 per Share [125% of the price of the Shares sold in the Offering]Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [ ], 2023, the date on which the Registration Statement on Form S-1 (File No. 333-267203) of the Company was declared effective by the Securities and Exchange Commission.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid pursuant to that certain Underwriting Agreement by or and between Aixin Life International, Inc., a Colorado Corporation (the “Company”), on behalf of Aegis Capital Corp. one hand, and Boustead Securities, LLC (the “Holder”), on the other hand, dated [ ], 2024 (the “Underwriting Agreement”), the Holder, as registered owner of this Purchase Warrant, to Trovagene, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] ], 2024 (the “Commencement Exercise Date”), and at or before 5:00 p.m., Eastern time, on [ ] [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] ], 2029 (the “Expiration Date”), which date shall be no more than five years from the commencement of sales of the initial public offering (the “Offering”), pursuant to the Underwriting Agreement, but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] shares of common stock of the Company, par value $0.0001 0.00001 per share (the “Common Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law or executive order to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ ] per Common Share [(125% of the price of the Shares sold per Common Share in the Offering]); provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Common Share and the number of Common Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price as set forth above or the adjusted exercise priceprice as a result of the events set forth in Section 6 below, depending on the context. Capitalized terms not defined herein shall have the meaning ascribed to them in the Underwriting Agreement.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. (“Holder”), as registered owner of this Purchase Warrant, to TrovageneCeres, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER FROM THE EFFECTIVE DATE OF PROSPECTUS] THE OFFERING (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ ] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUS] THE OFFERING (the “”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [____] shares of common stock of the Company, par value $0.0001 0.01 per share (the “Shares”), subject to adjustment as provided in Section 6 5 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [___] per Share [125150% of the price of the Shares sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 5 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. [___________] (“Holder”), as registered owner of this Purchase Warrant, to TrovageneBG Staffing, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] May [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] _], 2017 (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ ] May [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] _], 2021 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [________] shares of common stock of the Company, par value $0.0001 0.01 per share (the “Shares”), subject to adjustment as provided in Section 6 5 hereof. This Purchase Warrant will not be exercisable more than five years from the Firm Shares Closing Date pursuant to FINRA Rule 5110(f)(2)(G)(i). If the Expiration Date is a day on which banking institutions in the State of New York are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [___] per Share [125(120% of the price of the Shares sold in the Offering]); provided, however, that upon the occurrence of any of the events specified in Section 6 5 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. All capitalized terms used herein but not defined shall have the meanings given to them in the Underwriting Agreement dated as of May [_], 2016 by and among the Company and the underwriters party thereto.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. [__________] (“Holder”), as registered owner of this Purchase Warrant, to TrovageneMuscle Maker, Inc., a Delaware Nevada corporation (the “Company”), Holder is entitled, at any time or from time to time from [ [●] [DATE THAT IS ONE YEAR AFTER HUNDRED EIGHTY (180) DAYS FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ [●] [DATE THAT IS FIVE (5) YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] shares of common stock of the Company, par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 5 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [●] per Share [125120% of the price of the Shares sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 5 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. This Warrant is being issued pursuant to the certain Underwriting Agreement (the “Underwriting Agreement”), dated [●], 2020, by and among the Company, the Holder and other underwriters named therein, providing for the public offering (the “Offering”) of shares of common stock, par value $0.0001 per share, of the Company. The term “Effective Date” shall mean the effective date of the Registration Statement on Form S-1 (File No. 333-______). The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. [__________] (“Holder”), as registered owner of this Purchase Warrant, to TrovageneMuscle Maker, Inc., a Delaware Nevada corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] March 9, 2021 (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ ] [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] September 10, 2025 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] shares of common stock of the Company, par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 5 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ ] 2.04 per Share [125% of the price of the Shares sold in the Offering]Share; provided, however, that upon the occurrence of any of the events specified in Section 6 5 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. This Warrant is being issued pursuant to the certain Underwriting Agreement (the “Underwriting Agreement”), dated September 10, 2020, by and among the Company, the Holder and other underwriters named therein, providing for the public offering (the “Offering”) of shares of common stock, par value $0.0001 per share, of the Company. The term “Effective Date” shall mean the effective date of the Registration Statement on Form S-1 (File No. 333- 245047). The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid pursuant to that certain Underwriting Agreement by or and between Leaping Group Co., Ltd., a Cayman Islands limited liability company (the “Company”), on behalf of Aegis Capital Corp. one hand, and Boustead Securities, LLC, on the other hand, dated [●], 20[__] (the “Underwriting Agreement”), Boustead Securities, LLC (“Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS●], 20[__] (the “Commencement Exercise Date”), and at or before 5:00 p.m., Eastern time, [ ] on [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS●], 20[__] (the “Expiration Date”)Date”)1, but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] such number of ordinary shares of common stock of the Company, par value $0.0001 0.00284 per ordinary share (the “Ordinary Shares”) as equates to six and a half percent (6.5%) of the Ordinary Shares in the Offering (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ ] ____ per Ordinary Share [125(100% of the price of the Ordinary Shares sold in the Offering]); provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Ordinary Share and the number of Ordinary Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price as set forth above or the adjusted exercise priceprice as a result of the events set forth in Section 6 below, depending on the context. Capitalized terms not defined herein shall have the meaning ascribed to them in the Underwriting Agreement.

Purchase Warrant. THIS CERTIFIES THAT, in consideration for good and valuable consideration, the receipt and sufficiency of funds duly paid by or on behalf of Aegis Capital Corp. which is hereby acknowledged, ______________ (“Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ [________________] [DATE THAT IS ONE YEAR AFTER HUNDRED EIGHTY (180) DAYS FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ [____________] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [____] shares (the “Shares”) of common stock of the Companystock, par value $0.0001 per share (the “SharesCommon Stock”), of Silo Pharma, Inc., a Delaware corporation (the “Company”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized or required by law or executive order to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [●] per Share [equal to 125% of the price of the Shares shares sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. This Purchase Warrant is being issued in connection with a public offering of shares of Common Stock pursuant to the Company’s registration statement on Form S-1 (File No.: 333-261532 (the “Offering”). The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. As used herein, “Effective Date” means the date on which the Shares being sold in the Offering first become legally eligible for distribution to the public as determined in accordance with FINRA Conduct Rule 5110(a)(12). 1 NTD: To be 5% of the aggregate number of shares of common stock sold in the offering, including over-allotment shares.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. (“Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc.BiondVax Pharmaceuticals Ltd., a Delaware corporation company formed under the laws of the State Israel (the “Company”), Holder is entitled, at any time or from time to time from [ [________________] [DATE THAT IS ONE YEAR AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ [____________] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [____] [5% of Firm ADSs sold in Offering] ___________ ordinary shares of common stock of the Company, par value $0.0001 NIS 0.0000001 per share (the “Ordinary Shares”) represented by ______________ American Depositary Shares (“ADSs”), subject to adjustment as provided in Section 6 hereofhereof (the “Warrant ADSs”). If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [___] per Share Warrant ADS [125% of the price of the Shares ADS sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share Warrant ADS and the number of Shares Warrant ADSs to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. [•] (“Holder”), as registered owner of this Purchase Warrant, to TrovageneAuddia, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE •][DATE THAT IS ONE YEAR AFTER 180 DAYS FROM THE CLOSING DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ ] [DATE •][DATE THAT IS FIVE YEARS AFTER FIFTH ANNIVERSARY DATE OF PROSPECTUSCOMMENCEMENT DATE] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [•] shares (the “Warrant Shares”) of common stock of the Company, par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ $ [•] per Warrant Share [(125% of the price of the Shares shares of common stock sold in the proposed initial public offering of Shares (the “Offering]”); provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Warrant Share and the number of Warrant Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” means [•], the date that the Company’s Registration Statement on Form S-1 (File No: 333- [•]) was declared effective under the Securities Act of 1933, as amended (the “Securities Act”), by the U.S. Securities and Exchange Commission (the “Commission”).

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. A.G.P./Alliance Global Partners (“Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc.Flora Growth Corp., a Delaware corporation company incorporated in the Province of Ontario (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS] November 18, 2022, a date commencing one year from the Effective Date (as defined in the Underwriting Agreement) (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ ] [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] November 18, 2027 (the date that is five (5) years following the Commencement Date, the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] 400,000 shares (the “Shares”) of common stock of the Company, without par value $0.0001 per share (the “Common Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ ] 3.30 per Share [125% of the price of the Shares sold in the Offering]Share1; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. For the avoidance of doubt, this Purchase Warrant will be exercisable at any time, and from time to time, in whole or in part, from the Commencement Date, which period shall not extend further than five (5) years from the Commencement Date in compliance with FINRA Rule 5110(f)(2)(G)(i). 1 110% of the public offering price.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. EX Xxxxxx, division of Benchmark Investments, LLC. (“Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc.CW Petroleum Corp, a Delaware Wyoming corporation (the “Company”), Holder is entitled, at any time or from time to time from [ [________________] [DATE THAT IS ONE YEAR AFTER SIX MONTHS FROM THE DATE OF PROSPECTUSTHE COMMENCEMENT OF SALES OF THE PUBLIC SECURITIES IN THE INITIAL PUBLIC OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ [____________] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] [____]* shares of common stock of the Company, par value $0.0001 per share Company (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [●] per Share [125% of the price of the Shares sold in the Offering]OF THE PUBLIC OFFERING PRICE OF ONE UNIT SOLD IN THE OFFERING] per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term “Effective Date” shall mean [________], 2022, the date on which the Registration Statement on Form S-1 (File No. 333-265369) of the Company (“Registration Statement”) was declared effective by the Securities and Exchange Commission (“Commission”). This Purchase Warrant and the Shares exercisable hereby have been registered with the Commission on the Registration Statement and are thus freely tradeable.

Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of for value received, Aegis Capital Corp. or it assigns (each a “Holder” and collectively, the “Holders”), as registered owner of this Purchase Warrant, to Trovagene, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ time, in whole or in part, during a period commencing on [_________] [DATE THAT IS ONE YEAR AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [ ] [DATE THAT IS FIVE YEARS AFTER DATE OF PROSPECTUS] (the “Expiration Date”), but not thereafter, ) to subscribe for, purchase and receive, in whole or in part, up to [ an aggregate of [____] shares of common stock of the Companyordinary shares, par value $0.0001 NIS 1.00 per share (the “Shares”) of Mapi – Pharma Ltd., an Israeli corporation (the “Company”), subject to adjustment as provided in Section 6 hereofhereof the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified, as follows: (i) one quarter of this Purchase Warrant will have an exercise period of 48 months beginning on the Commencement Date, at an initial exercise price per ordinary share of $[•], which is equal to 150.0% of the initial public offering price per share of ordinary share; (ii) one half of this Purchase Warrant will have an exercise period of 42 months beginning six months after the Commencement Date, at an initial exercise price per ordinary share of $[•], which is equal to 200.0% of the initial public offering price per share of ordinary share; and (iii) one quarter of this Purchase Warrant will have an exercise period of 36 months beginning one year following the Commencement Date, at an initial exercise price per share of ordinary share of $[•], which is equal to 250.0% of the initial public offering price per share of ordinary share (each an “Expiration Date”). If the an applicable Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the applicable Expiration Date, the Company agrees not to take any action that would terminate the Purchase Warrant. This Purchase Warrant is initially exercisable at $[ ] per Share [125% of the price of the Shares sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean mean, as the case maybe, the applicable initial exercise price prices or the adjusted applicable exercise priceprices, depending on the context.

Purchase Warrant. THIS CERTIFIES THAT, pursuant to that certain Underwriting Agreement by and between Aerkomm Inc., a Nevada corporation (the “Company”) and Boustead Securities, LLC (“Boustead”), dated [●], 2018 (the “Underwriting Agreement”), Boustead (in consideration of funds duly paid by such capacity with its permitted successors or on behalf of Aegis Capital Corp. (assigns, the “Holder”), as registered owner of this Purchase Warrant, to Trovagene, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [ ] [DATE THAT IS ONE YEAR AFTER DATE OF PROSPECTUS●], 20[__] (the “Commencement Exercise Date”)) [THE DATE THAT IS THE EFFECTIVE DATE OF THE REGISTRATION STATEMENT], and at or before 5:00 p.m., Eastern time, [●], 20[ ] [DATE THAT IS FIVE YEARS AFTER FROM THE EFFECTIVE DATE OF PROSPECTUSTHE OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ [●] shares of common stock Common Stock of the Company, par value $0.0001 0.001 per share (the “Shares”), subject to adjustment as provided in Section 6 5 hereof. If the Expiration Date is a day on which banking institutions are authorized by law or executive order to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period commencing on the date hereof and ending on the Expiration Date, the Company agrees not to take any action that would terminate the this Purchase Warrant. This Purchase Warrant is initially exercisable at $[ [●] per Share [125(100% of the price of the Shares sold in the Offering]); provided, however, that upon the occurrence of any of the events specified in Section 6 5 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. Any term not defined herein shall have the meaning ascribed thereto in the Underwriting Agreement.